Acute promyelocytic leukemia cost-effectiveness of therapy: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
A limited number of cost-effective studies have been done. In summary, these studies showed that all-''trans'' retinoic acid-based therapy is more cost effective than chemotherapy. | A limited number of cost-effective studies have been done. In summary, these studies showed that all-''[[trans]]'' [[retinoic acid]]-based [[therapy]] is more cost effective than [[chemotherapy]]. | ||
==Cost-effectiveness of therapy== | ==Cost-effectiveness of therapy== | ||
Revision as of 15:17, 23 January 2019
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia cost-effectiveness of therapy |
|
FDA on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
CDC on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
Acute promyelocytic leukemia cost-effectiveness of therapy in the news |
|
Blogs on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
A limited number of cost-effective studies have been done. In summary, these studies showed that all-trans retinoic acid-based therapy is more cost effective than chemotherapy.
Cost-effectiveness of therapy
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.
- The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.[1]
- The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.